ROS-Induced DCTPP1 Upregulation Contributes to Cisplatin Resistance in Ovarian Cancer

ROS-Induced DCTPP1 Upregulation Contributes to Cisplatin Resistance in Ovarian Cancer

Cisplatin resistance hinders the improvement of the prognosis of patients with ovarian cancer. Cisplatin induces cancer cell apoptosis by inducing reactive oxygen species (ROS). dCTP pyrophosphatase 1 (DCTPP1) is a newly discovered dNTP pyrophosphatase. This study aimed to identify the role of DCTPP...

Full description

Bibliographic Details
Main Authors:	Yu Wang, Peishi Chen, Xueping Chen, Daoyuan Gong, Yingsong Wu, Liping Huang, Yao Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-02-01
Series:	Frontiers in Molecular Biosciences
Subjects:	ovarian cancer DCTPP1 cisplatin ROS cisplatin resistance
Online Access:	https://www.frontiersin.org/articles/10.3389/fmolb.2022.838006/full

Similar Items

ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer
by: Wenyu Wang, et al.
Published: (2020-11-01)

Pan-cancer landscape of DCTPP1 and preliminary exploration of DCTPP1 in renal clear cell carcinoma
by: Hongze Li, et al.
Published: (2024-11-01)

Comprehensive Analysis of the Expression and Prognosis for DCTPP1 gene in Breast Cancer
by: Tien Manh Hoang, et al.
Published: (2021-07-01)

BNIP3 contributes to cisplatin‐induced apoptosis in ovarian cancer cells
by: Jinghui Jia, et al.
Published: (2020-08-01)

DCTPP1 Expression as a Predictor of Chemotherapy Response in Luminal A Breast Cancer Patients
by: Juan P. Muñoz, et al.
Published: (2024-08-01)

Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo
by: Yurou Ji, et al.
Published: (2022-12-01)

HOXB2 promotes cisplatin resistance by upregulating lncRNA DANCR in ovarian cancer
by: Xiao Li, et al.
Published: (2024-06-01)

Synergism of antitumor action of dioxadet and cisplatin in model of ascitic ovarian tumor
by: V. G. Bespalov, et al.
Published: (2016-02-01)

Investigating the Effects of Morphine on Survival and Sensitivity to Cisplatin in Ovarian Cancer Cells
by: Maryam Rezaeigazik, et al.
Published: (2019-09-01)

Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells
by: Li Liu, et al.
Published: (2019-07-01)

Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway
by: Xuan Wei, et al.
Published: (2021-03-01)

Epigenetic editing of BRCA1 promoter increases cisplatin and olaparib sensitivity of ovarian cancer cells
by: Wanhong He, et al.
Published: (2024-12-01)

Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway
by: Xuan Wei, et al.
Published: (2021-09-01)

Protective Effect of Tyrosol on Cisplatin–Induced Ovarian Inflammation and Oxidative Stress in Rats
by: İshak Gökçek, et al.
Published: (2024-09-01)

The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells
by: Sung-How Sue, et al.
Published: (2024-09-01)

An enhanced antioxidant strategy of astaxanthin encapsulated in ROS-responsive nanoparticles for combating cisplatin-induced ototoxicity
by: Jiayi Gu, et al.
Published: (2022-06-01)

Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin
by: Shahana Dilruba, et al.
Published: (2020-02-01)

Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells
by: Yen-Ying Ma, et al.
Published: (2011-06-01)

Cisplatin Induced Nephrotoxicity
by: Seyed Seifollah Beladi Mousavi, et al.
Published: (2014-02-01)

Meta‐analysis of microarray data to determine gene indicators involved in the cisplatin resistance in ovarian cancer
by: Somayeh Hashemi Sheikhshabani, et al.
Published: (2023-12-01)

Cisplatin Suppresses Proliferation of Ovarian Cancer Cells through Inhibition Akt and Modulation MAPK Pathways
by: Jae-Sun Choi
Published: (2020-03-01)

Cytotoxicity of natural and synthetic cannabinoids and their synergistic antiproliferative effects with cisplatin in human ovarian cancer cells
by: Ying Chen, et al.
Published: (2024-11-01)

Cisplatin increases immune activity of monocytes and cytotoxic T-cells in a murine model of epithelial ovarian cancer
by: Daniel Hopkins, et al.
Published: (2021-12-01)

Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo
by: Bo Zhou, et al.
Published: (2019-11-01)

The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer
by: Kate Glennon, et al.
Published: (2021-08-01)

Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer
by: Linjuan Huang, et al.
Published: (2023-07-01)

GSTT1/GSTM1 deficiency aggravated cisplatin-induced acute kidney injury via ROS-triggered ferroptosis
by: Peipei Li, et al.
Published: (2024-09-01)

Synergistic effect of black tea polyphenol, theaflavin-3,3′-digallate with cisplatin against cisplatin resistant human ovarian cancer cells
by: Haibo Pan, et al.
Published: (2018-07-01)

Aspirin inhibits tumor progression and enhances cisplatin sensitivity in epithelial ovarian cancer
by: Jianfeng Guo, et al.
Published: (2021-08-01)

Metformin combined with cisplatin reduces anticancer activity via ATM/CHK2-dependent upregulation of Rad51 pathway in ovarian cancer
by: Jingjing Zhang, et al.
Published: (2024-11-01)

Deletion of NADPH oxidase 2 attenuates cisplatin-induced acute kidney injury through reducing ROS-induced proximal tubular cell injury and inflammation
by: Ho-Ching Chen, et al.
Published: (2023-03-01)

Galaxamide alleviates cisplatin-induced premature ovarian insufficiency via the PI3K signaling pathway in HeLa tumor-bearing mice
by: Huan Tao, et al.
Published: (2024-08-01)

Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low‐dose fraction radiation
by: Lili Zhao, et al.
Published: (2019-05-01)

Analysis of Secreted Proteins from Prepubertal Ovarian Tissues Exposed In Vitro to Cisplatin and LH
by: Serena Marcozzi, et al.
Published: (2022-04-01)

Enhancement of Cisplatin Sensitivity by Microwave Radiation in Ovarian Cancer Cells
by: Mansour Tayebi-khorami, et al.
Published: (2022-04-01)

Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients
by: Wu-yun Wang, et al.
Published: (2021-01-01)

Molecular mechanisms of cisplatin resistance in ovarian cancer
by: Chenying Jiang, et al.
Published: (2024-11-01)

Identification and validation of genes associated with prognosis of cisplatin-resistant ovarian cancer
by: Dajiang Liu, et al.
Published: (2024-08-01)

MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells
by: Meysam Moghbeli
Published: (2021-09-01)

Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer
by: Xiao-Yu Yan, et al.
Published: (2020-04-01)